Medication info
Mglie Tablets 25 mg (Empagliflozin)

Mglie Tablets 25 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceuticals Co., Ltd.
Appearance
Light yellow, biconvex, oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle
Approval status
Active

MFDS item code 202101970 · Approved 2021.03.03 · Insurance code 663608380

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).

Ingredients

Manufacturer
Korea Prime Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control
  • inability to control blood sugar
  • type 2 diabetes
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes. Initially, it can be administered as monotherapy, and if blood sugar control is insufficient with monotherapy, it may be used in combination with metformin, pioglitazone, sulfonylureas, insulin, DPP-4 inhibitors, etc. In particular, patients with concomitant cardiovascular disease should be carefully administered according to the specialist's instructions. This medication helps in blood sugar control in conjunction with dietary and exercise therapies and contributes to the improvement of the patient's health.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).

Precautions

This medication should not be administered to certain patients. Firstly, it should not be used in patients who are allergic to the active ingredient or any of the components of this medication. Additionally, it should not be given to patients with type 1 diabetes or those with diabetic ketoacidosis. Patients with severely impaired kidney function, i.e. glomerular filtration rate below 30 mL/min/1.73m2, end-stage renal disease, or those undergoing dialysis should also not use this medication. Since this medication contains lactose, it should be avoided in patients with lactose intolerance or genetic galactose metabolism disorders. In patients with slightly impaired kidney function, this medication should be administered cautiously. In cases where glomerular filtration rate is less than 60 mL/min/1.73m2, the dosage of this medication may need to be adjusted or discontinued. This medication is not recommended for patients with end-stage renal disease or those on dialysis, as its effects are not expected. Regular monitoring of kidney function before and during treatment is essential. In patients with mild to moderate heart failure, caution should be exercised, and it is not recommended in patients with severe heart failure. This medication may increase the risk of hypoglycemia when used in conjunction with drugs that can cause hypoglycemia such as insulin or sulfonylureas, so dosage adjustments of insulin or these medications may be necessary when used together. Possible adverse reactions that can occur while taking this medication include hypoglycemia, genitourinary infections, urinary tract infections, increased urination, fluid volume depletion, etc. In particular, genitourinary fungal infections may occur more commonly in women, requiring caution. Serious metabolic derangements such as ketoacidosis can rarely occur, so if symptoms such as vomiting, abdominal pain, breathing difficulties, or fatigue appear, immediate consultation with healthcare personnel is required. This medication can lead to fluid loss, so it must be used more cautiously in situations with a risk of dehydration or in elderly patients. Serious urinary tract infections such as urosepsis or pyelonephritis have been reported, so prompt evaluation and treatment are necessary if urinary tract infection symptoms occur. This medication increases the risk of genitourinary fungal infections, so patients with a history of such infections should be monitored closely. There is a risk of hypoglycemia when driving or operating machinery, especially when used in combination with insulin or sulfonylureas. Its use is not recommended during pregnancy, and if pregnancy is confirmed, it should be discontinued. During breastfeeding, it is also advisable to discontinue breastfeeding, as this medication may be excreted in breast milk. It is not used in children under 18 years of age, as safety and efficacy have not been established. In the case of overdose, the patient's condition should be closely monitored, and appropriate treatment should be provided; the effectiveness of removal through dialysis is not known. This medication should be stored out of reach of children, and transferring it to another container is not advisable as it may affect quality.

Side effects

  • Hypoglycemia
  • vulvar candidiasis
  • balanitis
  • other genital infections
  • increased urination
  • urinary tract infections
  • decreased fluid volume
  • dehydration
  • hypotension
  • decreased blood volume
Show 145 more
  • orthostatic hypotension
  • syncope
  • increased serum creatinine
  • decreased glomerular filtration rate
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic bleeding
  • soft tissue infection
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pneumonia
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • ureteral calculi
  • acute kidney injury
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • diabetic foot
  • lumbar pain
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • macular retinal detachment
  • limb injury
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • Prinzmetal angina
  • coronary artery disease
  • deep vein thrombosis
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumor
  • bladder cancer
  • gastric cancer
  • pancreatic adenocarcinoma
  • colorectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • ear pain
  • position-related vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • nasopharyngitis
  • shingles
  • lightheadedness
  • thoracic discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • decreased appetite
  • paroxysmal symptoms
  • vitamin D deficiency
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrotic changes
  • eye discomfort
  • eye congestion
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • phlegm retention
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • palpitations
  • tachycardia
  • atherosclerosis
  • diabetic vascular disorders
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is best to store it at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness safely.

Appearance and packaging

Appearance

Light yellow, biconvex, oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.